Navigate Up

UPMC/University of Pittsburgh Schools of the Health Sciences
For Journalists
Senior Manager
Telephone: 412-578-9193 or 412-624-3212
Manager
Telephone: 412-586-9776
Patient & Other Inquiries


Pitt Team to Lead Effort Exploring Alzheimer’s Biomarkers, Cognitive Function in Adults with Down Syndrome

PITTSBURGH, Nov. 19, 2015 – With the help of an estimated $12.5 million grant over five years from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), Alzheimer’s disease experts at the University of Pittsburgh will lead a multicenter effort exploring the progression of biomarkers of the disorder and cognitive function in people with Down syndrome.
 
Adults with Down syndrome typically show symptoms of Alzheimer’s by their 40s and have a 70 to 80 percent chance of developing clinical dementia by their 60s, said co-principal investigator Ben Handen, Ph.D., professor of psychiatry, Pitt School of Medicine. People with Down syndrome have three copies of chromosome 21, each containing a copy of the gene associated with the precursor protein for beta-amyloid, which is found in excess in the brains of Alzheimer’s patients.
 
“It’s apparent from Down syndrome patients that amyloid deposition is not sufficient to produce dementia,” Dr. Handen said. “These individuals have these deposits for more than a decade before cognitive decline is apparent. Understanding the relationships between Down syndrome, disease biomarkers and cognitive decline is critically important to help us design better therapies for all people with Alzheimer’s.”
 
In the Neurodegeneration in Aging Down Syndrome study (NiAD), researchers at four sites in the United States and the United Kingdom will monitor for five years 180 people older than 25 with Down syndrome and 40 people without the condition for factors including amyloid in blood and cerebrospinal fluid and on PET scans; structural and functional MRI scans; and cognitive/functional measures in 180 people older than 25 with Down syndrome.
 
Dr. Handen said, “The collaboration of several research institutions, each of which has worked independently in Alzheimer’s research, will strengthen our efforts by bringing together the largest biomarker studies going on in the general population.”
NiAD is part of the NIH’s Biomarkers of Alzheimer’s Disease in Adults with Down Syndrome Initiative, which supports teams of researchers using brain imaging, and fluid and tissue biomarkers in research that may one day lead to effective interventions for all people with dementia. 
 
“This is the first large-scale Alzheimer’s biomarker endeavor to focus on this high-risk group,” said Laurie Ryan, Ph.D., chief of the Dementias of Aging Branch in NIA’s Division of Neuroscience, which leads NIH research on Alzheimer’s. “Much like the long-established Alzheimer’s Disease Neuroimaging Initiative, the goal of this initiative is to develop biomarker measures that signal the onset and progression of Alzheimer’s in people with Down syndrome. Hopefully, one day, we also will use these biomarkers to determine the effectiveness of promising treatments.” 
 
The other sites are at the University of Wisconsin, Madison; Banner Alzheimer’s Institute in Phoenix; and Cambridge University, UK. The NiAD study is funded by NIA grant 1U01AG05140.

UPMC | Affiliated with the University of Pittsburgh Schools of the Health Sciences Supplemental content provided by Healthwise, Incorporated. To learn more, visit www.healthwise.org

For help in finding a doctor or health service that suits your needs, call the UPMC Referral Service at 412-647-UPMC (8762) or 1-800-533-UPMC (8762). Select option 1.

UPMC is an equal opportunity employer. UPMC policy prohibits discrimination or harassment on the basis of race, color, religion, ancestry, national origin, age, sex, genetics, sexual orientation, gender identity, marital status, familial status, disability, veteran status, or any other legally protected group status. Further, UPMC will continue to support and promote equal employment opportunity, human dignity, and racial, ethnic, and cultural diversity. This policy applies to admissions, employment, and access to and treatment in UPMC programs and activities. This commitment is made by UPMC in accordance with federal, state, and/or local laws and regulations.

Medical information made available on UPMC.com is not intended to be used as a substitute for professional medical advice, diagnosis, or treatment. You should not rely entirely on this information for your health care needs. Ask your own doctor or health care provider any specific medical questions that you have. Further, UPMC.com is not a tool to be used in the case of an emergency. If an emergency arises, you should seek appropriate emergency medical services.

UPMC
Pittsburgh, PA, USA | UPMC.com